GeneCentric Therapeutics, Inc. news
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma
Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles to anti-PD-(L)1 or IL-2 therap
Durham, NC, May 10, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today an upcoming presentation of initial results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancer) real-world study at the 2022 American Urological Association (AUA) Annual Meeting, which is being held in New Orleans, Louisiana, May 13-16
For two decades, scientists have been able to identify the molecular signature of specific cancers by isolating the RNA, responsible for dictating which proteins are produced and, by extension, how the cells behave in the body.
Now, Neil Hayes, MD, MS, MPH, director of the Center for Cancer Research at the University of Tennessee Health Science Center, and a colleague at Washington University in St. Louis, Jose P. Zevallos, MD, MPH, have identified a specific signature in frequently r
DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the upcoming oral presentation of the discovery and initial clinical utility of a novel signature that identifies patients with head and neck squamous cell carcinoma (HNSCC) that may benefit from treatment beyond typical surgical resection. The presentation will be made at the American Association for Cancer Research (AACR) Annual
The Piedmont Study, a Real-World Data Analysis in Patients Treated with Platinum Doublet Chemotherapy and/or Pembrolizumab, Identifies Predictive Biomarkers for Approved First-Line Treatments in NSCLC
DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a c